Advancement To Revolutionize Oral Drug Delivery
Zengen, Inc. announced today that its revolutionary drug delivery technology will be used in the new Chloraseptic® Relief Strips(tm), the only medicated oral strip for the treatment of sore throat. Zengens proprietary technology is the first to use drug active ingredients in an oral strip.
"We are excited to be part of the new generation of Chloraseptic products," said R. Steven Davidson, chief executive officer of Zengen. "Our technology holds promise to revolutionize the drug delivery industry because it marks the first time that drug active ingredients have been delivered utilizing an oral strip. This method is effective and convenient for consumers and may be more cost efficient for manufacturers."
The medicated oral strip is structured as a proprietary bilayer system. This system eliminates the use of irritating solvents and reduces damage due to heat and moisture, maintaining the integrity and efficacy of the active ingredients.
Certain auxiliary compounds used with the bilayer system can assist with rate of dissolution, water solubility, mucous adhesion and coating on the exterior film layer. For instance, depending on the auxiliary compounds used, Zengens oral strips can be manufactured to dissolve quickly or over an extended period of time, regulating the release of active material.
Previous technologies have proven too harsh, exposing the medical compound to extreme heat, moisture, compromising solvents and other irritants. With the creation of Chloraseptic Relief Strips, Zengen has established a new process which prevents the exposure to these harmful irritants and incorporates additional compounds to make the strips more suitable for various drug delivery needs.
"Chloraseptic Relief Strips bring true innovation to the cough/cold category and are a fitting extension of the Chloraseptic product line," said Elise Donahue, president and chief operating officer of Prestige Brands International. "Zengens technology has allowed us to make our product more convenient, accessible and modern for our consumers."
About Chloraseptic Relief Strips
New Chloraseptic Relief Strips are the first and only product of its kind to provide immediate and convenient relief of sore throat pain in an oral strip. The oral strips contain the active ingredients benzocaine and menthol. Chloraseptic Relief Strips will be available in major retail markets and drug stores beginning in September, 2003. The strips will be sold in two 20-count packs at a suggested retail price of $5.29.
About Zengen, Inc.
Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengens novel molecules offer broad-based anti-infective and anti-inflammatory solutions for multiple diseases and disorders, ranging from yeast infection to transplantation, and have the potential to significantly alter the way these diseases are treated. Through its wholly-owned subsidiary, InnoZen, Inc., Zengen develops and markets, or outlicenses, over-the-counter health products. In June 2003, InnoZen launched new OptiZen lubricating eye drops for instant relief from symptoms associated with Computer Vision Syndrome including eye dryness, burning and irritation. For more information about Zengen, please visit www.zengen.com
About Prestige Brands International
Prestige Brands is a consumer products company that was formed in 1999 for the purpose of buying and marketing popular consumer products. Prestiges first acquisition was Prell Shampoo, which the company purchased in November 1999. Subsequently, Prestige Brands purchased Chloraseptic Throat Sprays and Lozenges in March 2000, Comet Cleanser in 2001, and the Clear Eyes and Murine brands of eye drops and ear care products in 2003. Prestiges expertise is in marketing well-known brands to consumers via targeted advertising and promotion as well as identifying and developing new innovative line extensions that better meet consumers needs.
Kumiko Hakushi | Ruder Finn, Inc.
Finding new clues to brain cancer treatment
21.02.2020 | Case Western Reserve University
UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago
The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.
Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...
Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.
Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...
Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices
The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...
Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.
Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.
After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.
"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.
12.02.2020 | Event News
16.01.2020 | Event News
15.01.2020 | Event News
21.02.2020 | Medical Engineering
21.02.2020 | Health and Medicine
21.02.2020 | Physics and Astronomy